2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 426

Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registry
Abstract Number: 1496

Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
Abstract Number: 531

Expression of Indoleamine 2,3 Dioxygenase-1 and -2 in Focal Sialoadenitis of Patients with Sjögren’s Syndrome
Abstract Number: 1205

Expression of Lectin-like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis
Abstract Number: 2178

Extensive Natural Killer Cell Receptor Phenotyping on NK and T Cells Discloses Differences in RA and Psa, Potentially Mirroring Diverse Immunoregulatory Functions
Abstract Number: 828

Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study
Abstract Number: 215

External Hip Adduction Moment and Progression of Medial Tibiofemoral Cartilage Damage and Bone Marrow Lesions in Persons with Knee Osteoarthritis
Abstract Number: 2866

External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß₂-Glycoprotein I. a Prospective Multicentre Cohort Study
Abstract Number: 2168

Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation
Abstract Number: 1672

Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?
Abstract Number: 590

Factors Associated with a Poor Functional Prognosis in Early Inflammatory Back Pain: Results from the DESIR Cohort
Abstract Number: 272

Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Abstract Number: 2633

Factors Associated with Damage Accrual and Survival in Chinese Patients with Systemic Lupus Erythematosus (SLE): A Prospective Cohort Analysis of 747 Patients
Abstract Number: 1056

Factors Associated with Impairment on Quality of Life in Early or Established RA Patients
Abstract Number: 2384

Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].